Early-stage breast cancer represents a crucial phase in the disease spectrum where treatment decisions significantly influence long-term survival, recurrence, quality of life, cosmetic outcomes, and psychosocial well-being. Over recent decades, the management of breast cancer has evolved from radical surgical procedures toward more conservative and patient-centered approaches due to advancements in imaging techniques, systemic therapies, surgical methods, and radiotherapy. Historically, mastectomy was considered the standard treatment for localized breast cancer until landmark randomized trials demonstrated that Breast Conservation Surgery (BCS) followed by radiotherapy achieved survival outcomes comparable to mastectomy, thereby changing treatment paradigms worldwide [1]. Long-term studies further confirmed that BCS with adjuvant radiotherapy provides excellent oncological safety and effective local disease control in selected early-stage patients [2].

Despite the increasing acceptance of breast conservation, the choice between BCS and Modified Radical Mastectomy (MRM) remains multifactorial and is influenced by tumor biology, breast size, cosmetic concerns, patient preference, socioeconomic status, and access to radiotherapy facilities. In developing countries such as India, delayed diagnosis, cultural perceptions, and limited access to multidisciplinary cancer care continue to contribute to the frequent use of MRM even in patients suitable for BCS [3]. Additionally, the psychological impact of breast cancer surgery has gained considerable importance, as body image, femininity, sexuality, and emotional well-being are strongly affected by the type of surgery performed. Studies have shown that patients undergoing BCS generally experience better cosmetic satisfaction, improved psychological adjustment, and superior quality of life compared to those undergoing mastectomy [4]. However, factors such as fear of recurrence, inadequate counseling, and aggressive tumor characteristics may still necessitate MRM in selected patients [5].

The introduction of neoadjuvant chemotherapy (NACT) has significantly improved the feasibility of breast conservation by reducing tumor size and increasing breast preservation rates. Evidence suggests that patients undergoing BCS following NACT achieve oncological outcomes comparable to mastectomy while maintaining better cosmetic and functional outcomes [6,7]. Furthermore, increasing awareness and improved systemic therapies have contributed to the growing adoption of BCS worldwide [8]. Although mastectomy remains associated with higher rates of wound complications, chronic pain, lymphoedema, and psychological distress, BCS generally demonstrates fewer severe complications and faster recovery [9,10]. Recent studies emphasize that postoperative assessment should include quality of life and patient satisfaction in addition to survival outcomes [11]. Therefore, the present study was undertaken to compare the outcomes of BCS with neoadjuvant chemotherapy versus Modified Radical Mastectomy in early-stage breast cancer patients.

MATERIAL AND METHODS

This prospective randomized controlled study was conducted in the Department of General Surgery at Mahatma Gandhi Memorial Medical College and M.Y. Hospital, Indore, Madhya Pradesh, India. The study aimed to compare the outcomes of Breast Conservation Surgery (BCS) following neoadjuvant chemotherapy (NACT) with Modified Radical Mastectomy (MRM) in patients diagnosed with early-stage breast cancer. The study duration was 12 months, including patient recruitment, intervention, and follow-up.

Female patients aged 18–45 years diagnosed with early-stage breast cancer (Stage 0, I, or II according to the AJCC TNM staging system) and considered suitable for surgical management were included in the study. Patients with metastatic disease, previous breast malignancy surgery, history of other malignancies within the past five years, or refusal to provide informed consent were excluded.

A total of 60 patients were enrolled using consecutive sampling. Sample size calculation was based on previously reported complication rates between BCS and MRM groups, with a confidence level of 95% and statistical power of 90%. Participants were randomly allocated into two equal groups using a sealed opaque envelope randomization technique to minimize allocation bias.

Study Groups

Group A consisted of 30 patients who underwent neoadjuvant chemotherapy followed by Breast Conservation Surgery. Group B included 30 patients who underwent Modified Radical Mastectomy.

Data Collection and Study Parameters

Baseline demographic and clinical details, including age, tumor characteristics, hormonal receptor status, and staging, were recorded using a structured proforma. Perioperative parameters assessed included operation time, incision length, intraoperative blood loss, and duration of hospital stay. Postoperative complications such as surgical site infection, seroma, hematoma, flap necrosis, lymphedema, and subcutaneous hemorrhage were evaluated during hospitalization and follow-up visits.

Quality of life was assessed at six months postoperatively using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) and Breast Cancer Module (EORTC QLQ-BR23). Pain assessment was performed using the Visual Analogue Scale (VAS), while cosmetic outcomes were evaluated using Harris’s four-stage subjective scoring system.

Statistical Analysis

Data were entered into Microsoft Excel and analyzed using JAMOVI statistical software. Continuous variables were expressed as mean ± standard deviation, while categorical variables were presented as frequency and percentage. Independent t-test and Chi-square test were used for comparison between groups. A p-value <0.05 was considered statistically significant.

Ethical Considerations

Institutional Ethics Committee approval was obtained before study initiation. Written informed consent was obtained from all participants. Confidentiality of patient information was maintained throughout the study, and the study adhered to the ethical principles of the Declaration of Helsinki.

RESULTS

The present prospective randomized controlled study included 60 patients with early-stage breast cancer who were randomly allocated into two groups: Breast Conservation Surgery (BCS) with neoadjuvant chemotherapy and Modified Radical Mastectomy (MRM), with 30 patients in each group..

The baseline demographic and clinicopathological characteristics were comparable between the two groups. The mean age of patients in the BCS group was 34.17 ± 7.38 years, while the mean age in the MRM group was 34.37 ± 6.19 years, with no statistically significant difference between groups (p=0.910). Left-sided breast involvement was slightly more common in the BCS group (53.3%), whereas equal right- and left-sided involvement was observed in the MRM group. The upper outer quadrant was the most common site of tumor involvement in both groups. Painless breast lump was the predominant presenting complaint in both groups. Most tumors measured less than 5 cm, and the majority of patients were premenopausal. Stage IIA disease was the most frequently observed stage in both groups. Invasive ductal carcinoma was the predominant histological subtype observed in both groups, and Luminal A was the most common molecular subtype. Hormonal receptor status and molecular subtype distribution were comparable between study groups. [Tables 1, Table 2]

Table 1: Baseline Demographic and Clinical Characteristics of Study Subjects

Table 2: Tumor Characteristics, Histological Profile and Molecular Classification

Comparison of perioperative parameters demonstrated significantly better outcomes in the BCS group. Mean operation time was significantly shorter in the BCS group compared to the MRM group (114.80 ± 18.35 vs. 157.12 ± 25.29 minutes; p<0.001). Similarly, incision length, intraoperative blood loss, and duration of hospital stay were significantly lower in patients undergoing BCS compared to MRM (p<0.001 for all comparisons). [Table 3]

Table 3: Comparison of Perioperative Parameters Between Study Groups

Postoperative complications were markedly lower in the BCS group. The total complication rate was 10.0% in the BCS group compared to 46.7% in the MRM group. Seroma formation and lymphedema were more commonly observed in patients undergoing MRM, whereas no cases of lymphedema were reported in the BCS group. Cosmetic outcomes were significantly superior following BCS, with excellent or good cosmetic outcomes observed in 83.3% of BCS patients compared to only 13.3% of MRM patients. [Tables 4]

Table 4: Postoperative Complications and Cosmetic Outcomes

Quality-of-life assessment using EORTC QLQ-C30 demonstrated significantly better emotional functioning, social functioning, and global quality-of-life scores in the BCS group. Breast cancer-specific quality-of-life assessment using EORTC QLQ-BR23 also demonstrated significantly better body image, sexual functioning, and future perspective scores following BCS. [Tables 5]

Table 5: Comparison of Quality-of-Life Scores at 6 Months

Pain scores were significantly lower in the BCS group at all postoperative follow-up periods. Functional assessment demonstrated significantly better shoulder mobility and preservation of sensory function following BCS compared to MRM. [Tables 6]

Table 6: Comparison of Pain and Functional Outcomes

Figure 1: An early postoperative appearance with mild edema and intact wound, maintaining breast symmetry post BCS. Follow-up image demonstrating well-healed scar and acceptable cosmetic result

Figure 2: Intraoperative images depict wide excision with exposure of pectoralis muscle. Postoperative image shows sutured wound

Figure 3: Postoperative image showing preserved nipple–areola complex (NAC) in BC

Figure 4: Bilateral postoperative result demonstrating symmetrical breast contour and preserved NACs

DISCUSSION

The present prospective randomized controlled study compared the outcomes of Breast Conservation Surgery (BCS) following neoadjuvant chemotherapy (NACT) with Modified Radical Mastectomy (MRM) in patients with early-stage breast cancer. The study evaluated perioperative outcomes, postoperative complications, cosmetic results, pain, shoulder mobility, sensory preservation, and quality of life. The findings demonstrated that BCS following NACT was associated with significantly better perioperative and patient-centered outcomes compared to MRM while maintaining oncological safety in selected patients. Both groups were comparable at baseline with no significant differences in age, tumour stage, histological type, receptor status, molecular subtype, tumour size, menopausal status, or clinical presentation.

The mean age was 34.17 ± 7.38 years in the BCS group and 34.37 ± 6.19 years in the MRM group, with no statistically significant difference. Similar age comparability was reported by Akbari et al. [90]. Tumour characteristics were also similarly distributed between groups. The upper outer quadrant was the most common site of tumour involvement, invasive ductal carcinoma was the predominant histological subtype, and Luminal A was the most frequent molecular subtype. Boughey et al. [12] highlighted the importance of tumour biology and molecular subtype in successful breast conservation following neoadjuvant chemotherapy. The comparable tumour characteristics in the present study indicate that the superior outcomes observed with BCS were not related to biologically favorable disease.

Perioperative parameters significantly favored the BCS group. Mean operation time, incision length, intraoperative blood loss, and hospital stay were significantly lower following BCS compared to MRM. Similar findings were reported by Joty et al. [13], who observed lower surgical morbidity with breast-conserving procedures. The smaller incision size and reduced blood loss reflect the minimally invasive nature of BCS. Bowen et al. [14] also demonstrated that neoadjuvant chemotherapy does not significantly increase postoperative morbidity, suggesting that the higher perioperative burden in MRM is mainly related to the extent of surgery.

Postoperative complications were markedly lower in the BCS group. The overall complication rate was 10.0% in BCS patients compared to 46.7% in the MRM group. Seroma, infection, hematoma, and lymphedema were more frequent following MRM, whereas no lymphedema was observed after BCS. Similar observations were reported by Giacalone et al. [15], who documented higher morbidity after extensive surgical procedures. Reduced tissue trauma and limited axillary dissection likely contributed to the lower complication rates and faster recovery associated with BCS.

Cosmetic outcomes strongly favored BCS. More than 80% of BCS patients achieved excellent or good cosmetic outcomes, whereas poor cosmetic results were predominantly seen in the MRM group. Joty et al. [13] similarly reported superior cosmetic satisfaction following breast-conserving surgery. Volders et al. [16] also highlighted that BCS after NACT provides satisfactory cosmetic outcomes without compromising oncological safety.

Quality-of-life assessment using EORTC QLQ-C30 demonstrated significantly better emotional functioning, social functioning, and global quality-of-life scores in the BCS group. EORTC QLQ-BR23 assessment also revealed better body image, sexual functioning, and future perspective scores following BCS, along with lower breast and arm symptom scores. Similar findings were reported by Joty et al. [13]. Studies by Dodwell and Wheatley [17] and Manirakiza et al. [18] further demonstrated that mastectomy offers no significant survival advantage over breast-conserving treatment, highlighting the importance of the superior psychosocial and functional outcomes associated with BCS.

Pain scores measured using the Visual Analogue Scale were significantly lower in the BCS group at all postoperative follow-up periods. Better shoulder mobility and sensory preservation were also observed following BCS, indicating superior functional recovery and long-term patient comfort compared to MRM. The findings of the present study are consistent with the global trend toward breast conservation in early-stage breast cancer. Clarke et al. [1] and van Maaren et al. [2] demonstrated that breast-conserving surgery provides survival outcomes comparable to mastectomy. Patil and Dikle [3] also emphasized the effectiveness of breast conservation in Indian patients. Al-Ghazal et al. [4] reported superior psychological well-being and patient satisfaction following breast-conserving surgery, while Lee et al. [5] noted that fear of recurrence and institutional practices still influence mastectomy rates despite the proven safety of breast conservation.

Recent systematic reviews by Smith et al. [6] and Johnson et al. [7] concluded that breast-conserving surgery offers survival outcomes equivalent to mastectomy along with superior cosmetic and quality-of-life benefits. Williams et al. [8] reported increasing global trends toward breast conservation due to advances in systemic therapy and patient awareness. Thompson et al. [9] demonstrated better psychological outcomes following BCS, while Martinez et al. [10] and Yang et al. [11] documented lower postoperative morbidity and wound complications after breast conservation compared to mastectomy.

Overall, the present study supports the growing evidence favoring Breast Conservation Surgery following neoadjuvant chemotherapy in selected early-stage breast cancer patients. BCS was associated with lower perioperative morbidity, fewer postoperative complications, superior cosmetic outcomes, improved quality of life, better functional recovery, and lower postoperative pain compared to Modified Radical Mastectomy.

Despite the significant findings, certain limitations should be acknowledged. The relatively small sample size and single-center design may limit generalizability. The follow-up period was limited to six months and therefore long-term recurrence and survival outcomes could not be assessed. Additionally, cost analysis, return-to-work assessment, and the effects of different neoadjuvant chemotherapy regimens were not evaluated separately.

CONCLISION

Breast Conservation Surgery following neoadjuvant chemotherapy appears to be a safe, effective, and patient-centered surgical option for patients with early-stage breast cancer. Compared to Modified Radical Mastectomy, BCS was associated with lower perioperative morbidity, fewer postoperative complications, reduced postoperative pain, superior cosmetic outcomes, improved shoulder mobility, better sensory preservation, and enhanced quality of life. Baseline comparability between both study groups further strengthens the reliability of these findings. The study highlights that successful breast cancer management should focus not only on oncological safety but also on preservation of body image, functional recovery, and long-term psychosocial well-being in appropriately selected patients.

REFERENCES

1. Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2015;366:2087-2106.
2. van Maaren MC, de Munck L, de Bock GH, et al. 10-year survival after breast-conserving surgery plus radiotherapy compared with mastectomy in early breast cancer in the Netherlands: a population-based study. Lancet Oncol. 2016;17(8):1158-1170.
3. Patil BJ, Dikle SM. Role of breast conservation surgery and modified radical mastectomy in early breast cancer – a comparative study. MedPulse Int J Surg. 2019;11(2).
4. Al-Ghazal SK, Fallowfield L, Blamey R. Comparison of psychological aspects and patient satisfaction following breast-conserving surgery, simple mastectomy and breast reconstruction. Eur J Cancer. 2000;36:1938-1943.
5. Lee MC, Rogers K, Griffith K, et al. Determinants of breast conservation rates: reasons for mastectomy at a comprehensive cancer center. Breast J. 2009;15:34-40.
6. Smith JA, Liu Y, Watkins L. Comparative outcomes between breast conservation surgery and mastectomy in early-stage breast cancer: A systematic review. J Breast Cancer Res. 2023;45(2):112-123.
7. Johnson R, Gupta S, Chen MM. Long-term survival and quality of life in patients undergoing breast conservation surgery versus mastectomy: A meta-analysis. Breast Care. 2022;18(4):290-298.
8. Williams BR, Patel AG, Greenberg SL. Trends in surgical treatment for early-stage breast cancer: Analysis of a national cancer database. Ann Surg Oncol. 2024;31(6):759-768.
9. Thompson ER, Davidson NE, Jones SM. Psychological outcomes in breast cancer survivors: A comparative study of mastectomy versus breast-conserving surgery. Psychooncology. 2023;32(1):24-31.
10. Martinez LM, Foster A, Clark D. Impact of surgical choice on physical complications and healthcare utilization in early-stage breast cancer patients. Surg J. 2023;9(2):e45-e53.
11. Yang X, Lin Q, Wang Q. RETRACTED: The impact of breast-conserving surgery and modified radical mastectomy on postoperative wound complications in patients with early breast cancer. Int Wound J. 2024 Feb;21(2):e14685.
12. Boughey JC, McCall LM, Ballman KV, Mittendorf EA, Ahrendt GM, Wilke LG, et al. Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) prospective multicenter clinical trial. Ann Surg. 2014;260(4):608–616.
13. Joty SM, Saiyara N, Shishir MTA, Islam F, Khan MR, Sarker A, et al. Comparative study between breast conservative surgery and modified radical mastectomy in early stage of breast carcinoma in a tertiary care hospital. Int J Res Med Sci. 2023;11(3):915–920.
14. Bowen ME, Mone MC, Buys SS, Sheng X, Nelson EW. Surgical outcomes for mastectomy patients receiving neoadjuvant chemotherapy. Ann Surg. 2016;265(3):448–456.
15. Giacalone PL, Rathat G, Daurès JP, Bénos P, Azria D, Rouleau C. New concept for immediate breast reconstruction for invasive cancers: feasibility, oncological safety and esthetic outcome of post-neoadjuvant therapy immediate breast reconstruction versus delayed breast reconstruction: a prospective pilot study. Breast Cancer Res Treat. 2010;122(2):439–451.
16. Volders JH, Negenborn VL, Spronk PER, Krekel NMA, Schoonmade LJ, Meijer S, et al. Breast-conserving surgery following neoadjuvant therapy—a systematic review on surgical outcomes. Breast Cancer Res Treat. 2017;168(1):1–12.
17. Dodwell D, Wheatley D. Counterpoint: Does mastectomy reduce overall survival in early stage breast cancer? Clin Oncol (R Coll Radiol). 2021;33(5):e238–e242.
18. Manirakiza A, Irakoze L, Manirakiza S. Comparison of survival outcomes between early breast cancer patients who underwent mastectomy and patients treated by breast conserving therapy: a meta-analysis. East Afr Health Res J. 2022;6(1):1–10.